+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ophthalmic Drugs Market - Global Forecast 2026-2032- Product Image
Ophthalmic Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Ophthalmic Drugs Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968753
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ophthalmic Drugs Market is projected to reach USD 45.86 Billion in 2026. It is expected to continue growing at a CAGR of 9.16%, reaching USD 77.72 Billion by 2032.

The ophthalmic drugs market is expanding as vision care shifts from episodic treatment to long-term disease management across glaucoma, dry eye disease, retinal disorders, ocular inflammation, allergy, infection, and rare inherited eye diseases. Demand is supported by population aging, diabetes prevalence, high screen exposure, and broader diagnosis of chronic ocular surface and retinal conditions.

Public health agencies continue to underscore the scale of need: the World Health Organization reports that at least 2.2 billion people live with near or distance vision impairment, and at least 1 billion cases could have been prevented or remain unaddressed. This creates sustained demand for prescription eye drops, anti-VEGF injections, corticosteroids, immunomodulators, antibiotics, biologics, biosimilars, and emerging gene and cell therapies.

Transformative Shifts in Ophthalmic Therapeutics

The ophthalmic therapeutics landscape is being reshaped by longer-acting retinal therapies, preservative-free formulations, sustained-release delivery, and biosimilar competition in anti-VEGF treatment. These shifts are important because adherence remains a major challenge in chronic eye diseases such as glaucoma and dry eye disease, where patient persistence directly affects outcomes.

Regulators are also widening the innovation pathway for specialty ophthalmology. Recent approvals in geographic atrophy, dry eye disease, inherited retinal disease, and biosimilar ranibizumab demonstrate a market moving beyond traditional topical therapy toward targeted biologics, complement inhibition, and precision medicine.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across ophthalmic drug development, diagnosis, and patient monitoring. FDA-cleared autonomous AI for diabetic retinopathy screening has validated the clinical relevance of algorithm-supported eye care, while AI-assisted image analysis is improving trial eligibility, lesion quantification, and disease progression tracking in retinal disorders.

For ophthalmic drug manufacturers, AI can reduce operational friction by improving patient identification, optimizing clinical trial site selection, monitoring real-world safety signals, and supporting personalized adherence programs. The strongest commercial value is expected where AI is paired with retinal imaging, electronic health records, and connected care models.

Key Regional Insights for Ophthalmic Drugs

Asia-Pacific is one of the most important growth engines for ophthalmic drugs due to large aging populations, rising diabetes burden, and expanding access to specialty eye care in China, India, Japan, South Korea, Australia, and ASEAN markets. The International Diabetes Federation identifies Asia as a major center of diabetes burden, reinforcing demand for diabetic retinopathy screening and retinal therapies. Japan and Australia support high-value adoption of innovative retinal and glaucoma therapies, while China and India provide scale for branded generics, biosimilars, and affordable chronic eye disease treatment.

North America remains a premium innovation market, led by the United States’ concentration of ophthalmology specialists, clinical trial activity, reimbursement infrastructure, and FDA approvals for novel retinal and ocular surface therapies. Europe combines strong regulatory standards with broad public health systems, making market access, pharmacoeconomic evidence, and country-level reimbursement negotiations central to uptake across glaucoma, age-related macular degeneration, dry eye disease, and inflammatory eye disorders.

Latin America is advancing through expanding private ophthalmology networks and demand for glaucoma, dry eye, infection, and retinal disease therapies, with Brazil and Mexico serving as important commercial anchors. The Middle East, particularly GCC countries, is investing in specialty healthcare infrastructure and tertiary eye hospitals, while Africa’s opportunity is shaped by access expansion, essential medicines availability, workforce capacity, and preventable blindness programs supported by global eye health initiatives.

Key Group Insights Across Global Alliances

ASEAN markets are gaining relevance as urbanization, diabetes prevalence, and healthcare investment increase demand for accessible ophthalmic drugs, particularly for glaucoma, infection, allergy, dry eye disease, and diabetic eye complications. GCC countries are more focused on premium specialty care, hospital-based ophthalmology, imported innovative therapies, and integrated public-private healthcare delivery supported by national healthcare modernization programs.

The European Union represents a highly regulated but commercially significant bloc where centralized and national regulatory processes, health technology assessment, and reimbursement rules shape adoption. BRICS markets combine high patient volume with increasing domestic pharmaceutical manufacturing and biosimilar capacity, making pricing strategy, local evidence generation, and regional partnerships essential for sustainable access.

G7 countries remain central to ophthalmic drug innovation, regulatory precedent, clinical guideline development, and premium therapy adoption, particularly in the United States, Japan, Germany, France, Italy, the United Kingdom, and Canada. NATO-aligned markets broadly benefit from mature procurement systems, established pharmacovigilance frameworks, and high clinical standards, although reimbursement timing, prescribing restrictions, and formulary access vary widely.

Key Country Insights in Ophthalmic Drugs

The United States leads global commercialization for ophthalmic drugs through strong specialty prescribing, FDA innovation pathways, extensive retina clinic networks, and high use of injectable retinal therapies. Canada emphasizes evidence-based reimbursement and public-private coverage coordination, while Mexico and Brazil provide growth through expanding private care and rising treatment of glaucoma, dry eye, ocular infection, allergy, and diabetic eye disease.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine large aging populations with structured reimbursement systems, making health economics, comparative effectiveness, and real-world evidence critical for market access. Russia remains a distinct market shaped by localization, affordability, public procurement, and access to essential ophthalmic medicines for chronic and infectious eye conditions.

China and India are high-scale markets driven by diabetes, myopia, cataract-related care pathways, and local manufacturing capacity for generics and biosimilars. Japan supports advanced ophthalmic innovation and high clinical adoption, South Korea combines technology-led care with strong specialty access and retinal imaging utilization, and Australia maintains a mature reimbursement environment for high-value ophthalmology therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated assets that solve clear clinical problems, including longer dosing intervals, improved tolerability, preservative-free delivery, sustained-release formats, and stronger real-world adherence. Commercial success will increasingly depend on demonstrating durable outcomes, payer value, safety, and ease of integration into ophthalmology workflows.

Companies should strengthen regional evidence strategies, expand partnerships with retina, glaucoma, cornea, and ocular surface specialists, and use AI-enabled screening or monitoring to improve patient identification. Manufacturers also need resilient supply chains, biosimilar defense strategies, pharmacovigilance readiness, and access models tailored to mature, emerging, and essential-medicine markets.

Research Methodology

This executive summary is developed through secondary research and market intelligence synthesis using publicly available and verifiable sources, including regulatory agency communications, public health data, clinical guideline trends, peer-reviewed literature, healthcare policy references, disease burden databases, and ophthalmology treatment pathway reviews.

The analysis applies triangulation across disease burden, product innovation, regulatory activity, reimbursement dynamics, regional healthcare infrastructure, access conditions, and competitive positioning. Insights are validated for consistency with known ophthalmology treatment pathways, current industry developments, and documented public health priorities, while excluding market sizing, market share, and forecasting assumptions.

Conclusion

The ophthalmic drugs market is entering a more specialized phase defined by biologics, biosimilars, sustained-release platforms, AI-enabled diagnostics, and precision approaches for retinal and ocular surface diseases. Demand remains structurally supported by aging, diabetes, digital lifestyle exposure, and the global burden of preventable vision impairment.

Companies that align clinical differentiation with affordability, evidence generation, and regional access strategies will be best positioned to strengthen competitiveness. The most successful participants will combine therapeutic innovation with delivery convenience, data-driven patient identification, robust safety monitoring, and strong payer-relevant outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Ophthalmic Drugs Market, by Product Type
7.1. Introduction
7.2. Over-The-Counter Drugs
7.3. Prescription Drugs
8. Ophthalmic Drugs Market, by Drug Class
8.1. Introduction
8.2. Anti-Allergics
8.2.1. Antihistamines
8.2.2. Mast Cell Stabilizers
8.3. Anti-Glaucoma Agents
8.3.1. Alpha-Adrenergic Agonists
8.3.2. Beta-Blockers
8.3.3. Carbonic Anhydrase Inhibitors
8.3.4. Prostaglandin Analogs
8.4. Anti-Inflammatories
8.4.1. Corticosteroids
8.4.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
8.5. Anti-VEGF Agents
8.5.1. Aflibercept
8.5.2. Brolucizumab
8.5.3. Ranibizumab
8.6. Antibiotics
8.6.1. Aminoglycosides
8.6.2. Fluoroquinolones
8.6.3. Macrolides
8.6.4. Tetracyclines
8.7. Antifungal
8.8. Antiviral
8.8.1. Acyclovir
8.8.2. Ganciclovir
8.8.3. Trifluridine
8.8.4. Valaciclovir
9. Ophthalmic Drugs Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intracameral injection
9.2.2. Intravitreal Injections
9.3. Oral
9.3.1. Capsules
9.3.2. Tablets
9.4. Topical
9.4.1. Eye Drops
9.4.2. Gels
9.4.3. Ointments
10. Ophthalmic Drugs Market, by Therapeutic Area
10.1. Introduction
10.2. Age Related Macular Degeneration (AMD)
10.2.1. Dry AMD
10.2.2. Wet AMD
10.3. Cataracts
10.4. Conjunctivitis
10.5. Diabetic Retinopathy
10.6. Dry Eye Syndrome
10.7. Glaucoma
10.8. Ocular Infections
11. Ophthalmic Drugs Market, by Patient Demographics
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Ophthalmic Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Home Care Settings
12.4. Hospitals
12.5. Ophthalmic Clinics
13. Ophthalmic Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Ophthalmic Drugs Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Ophthalmic Drugs Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Ophthalmic Drugs Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Australia
16.10. Italy
16.11. Brazil
16.12. Mexico
16.13. South Korea
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Ajanta Pharma Ltd.
18.3. Alcon Vision LLC
18.4. Apotex Inc.
18.5. Bausch Health Companies Inc.
18.6. Bayer AG
18.7. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
18.8. Cipla Limited
18.9. EyePoint Pharmaceuticals, Inc.
18.10. F. Hoffmann-La Roche Ltd
18.11. Intas Pharmaceuticals Ltd.
18.12. Johnson & Johnson Service, Inc.
18.13. KODIAK SCIENCES INC.
18.14. Lotus Pharmaceuticals
18.15. Lupin Limited
18.16. Merck & Co., Inc.
18.17. Nicox SA
18.18. Novartis AG
18.19. Ocular Therapeutix, Inc.
18.20. OCuSOFT Inc.
18.21. Otsuka Pharmaceutical Co., Ltd.
18.22. Outlook Therapeutics, Inc.
18.23. Pfizer Inc.
18.24. Regeneron Pharmaceuticals Inc.
18.25. Santen Pharmaceutical Co., Ltd.
18.26. Senju Pharmaceutical Co.,Ltd.
18.27. Somerset Pharma, LLC.
18.28. Sun Pharmaceutical Industries Ltd.
18.29. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL OPHTHALMIC DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OPHTHALMIC DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OPHTHALMIC DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OPHTHALMIC DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-ALLERGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-ALLERGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-ALLERGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MAST CELL STABILIZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MAST CELL STABILIZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MAST CELL STABILIZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ANTI-GLAUCOMA AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ANTI-GLAUCOMA AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTI-GLAUCOMA AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BETA-BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BETA-BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BETA-BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-INFLAMMATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-INFLAMMATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ANTI-INFLAMMATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL AFLIBERCEPT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL AFLIBERCEPT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL AFLIBERCEPT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BROLUCIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BROLUCIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BROLUCIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIFUNGAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIFUNGAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ANTIFUNGAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ANTIVIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIVIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ANTIVIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ACYCLOVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ACYCLOVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ACYCLOVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL GANCICLOVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GANCICLOVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL GANCICLOVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL TRIFLURIDINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL TRIFLURIDINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TRIFLURIDINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL VALACICLOVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL VALACICLOVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL VALACICLOVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INTRACAMERAL INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INTRACAMERAL INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL INTRACAMERAL INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL INTRAVITREAL INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL INTRAVITREAL INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INTRAVITREAL INJECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL EYE DROPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL EYE DROPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL EYE DROPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL DRY AMD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL DRY AMD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL DRY AMD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL WET AMD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL WET AMD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL WET AMD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL CATARACTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL CATARACTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL CATARACTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL GLAUCOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL OCULAR INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL OCULAR INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL OCULAR INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL OPHTHALMIC CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL OPHTHALMIC CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL OPHTHALMIC CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 201. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 202. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 203. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 204. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 205. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 206. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 207. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 208. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 209. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 211. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 212. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 213. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 214. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 215. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 216. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 219. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 220. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 221. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 222. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 223. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 224. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 225. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 226. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 227. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 229. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 230. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 231. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 232. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 233. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 234. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 236. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 237. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 238. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 239. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 240. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 241. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 242. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 243. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 244. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 245. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 247. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 248. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 249. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 250. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 251. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 252. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 255. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 256. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 257. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 258. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 259. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 260. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 261. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 262. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 263. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 264. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 265. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 266. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 267. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 268. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 269. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 270. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 273. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 274. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 275. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 276. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 277. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 278. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 279. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 280. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 281. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 283. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 284. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 285. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 286. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 287. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 288. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 291. NATO OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 292. NATO OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 293. NATO OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 294. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 295. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 296. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 297. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 298. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 299. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 300. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 301. NATO OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 302. NATO OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 303. NATO OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 304. NATO OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 305. NATO OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 306. NATO OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 307. NATO OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. NATO OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. G7 OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 310. G7 OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 311. G7 OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 312. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 313. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 314. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 315. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 316. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 317. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 318. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. G7 OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 320. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 321. G7 OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 322. G7 OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 323. G7 OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 324. G7 OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 325. G7 OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. G7 OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 327. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 328. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 329. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 330. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 331. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 332. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 333. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 334. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 335. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 336. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 337. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 338. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 339. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 340. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 341. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 342. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 343. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 345. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 346. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 347. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 348. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 349. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 350. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 351. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 352. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 353. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 354. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 355. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 356. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 357. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 358. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 359. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2017-2032 (USD MILLION)
TABLE 360. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 361. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 362. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 363. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 364. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 365. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 366. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2017-2032 (USD MILLION)
TABLE 367. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2017-2032 (USD MILLION)
TABLE 368. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2017-2032 (USD MILLION)
TABLE 369. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2017-2032 (USD MILLION)
TABLE 370. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 371. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2017-2032 (USD MILLION)
TABLE 372. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 373. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)

Companies Mentioned

  • AbbVie Inc.
  • Ajanta Pharma Ltd.
  • Alcon Vision LLC
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Cipla Limited
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Service, Inc.
  • KODIAK SCIENCES INC.
  • Lotus Pharmaceuticals
  • Lupin Limited
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Outlook Therapeutics, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co.,Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 45.86 Billion
Forecasted Market Value ( USD ) by 2032 $ 77.72 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Ophthalmic Drug Delivery System Market - Global Forecast 2026-2032 - Product Image

Ophthalmic Drug Delivery System Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Ophthalmic Packaging Market - Global Forecast 2026-2032 - Product Image

Ophthalmic Packaging Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report - Product Image

Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Ophthalmic Drugs - Global Strategic Business Report - Product Image

Ophthalmic Drugs - Global Strategic Business Report

  • Report
  • 478 Pages
  • Global
From
Ophthalmic Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2032 - Product Image

Ophthalmic Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2032

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.